Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sandor L. Varga is active.

Publication


Featured researches published by Sandor L. Varga.


Journal of Medicinal Chemistry | 1983

Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.

John J. Baldwin; Marcia E. Christy; George H. Denny; Charles N. Habecker; Mark B. Freedman; Paulette A. Lyle; Gerald S. Ponticello; Sandor L. Varga; Dennis M. Gross; Charles S. Sweet

A series of 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazoles is described. The compounds were investigated in vitro for beta-adrenoceptor antagonism, and several examples were found to be selective for the beta 1-adrenoceptor. The structure--activity relationship exhibited by this series of compounds is discussed. (S)-2-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]-4-(2 -thienyl)imidazole [(S)-13] was over 100 times more selective than atenolol for the beta 1-adrenergic receptor and has been selected for in-depth studies.


Journal of Organic Chemistry | 1986

On the use of the O-methylmandelate ester for establishment of absolute configuration of secondary alcohols

Barry M. Trost; J. L. Belletire; Stephen A. Godleski; Patrick G. McDougal; James M. Balkovec; John J. Baldwin; Marcia E. Christy; Gerald S. Ponticello; Sandor L. Varga; James P. Springer


Journal of the American Chemical Society | 1972

Acetamidomethyl. A Novel Thiol Protecting Group for Cysteine

Daniel F. Veber; John D. Milkowski; Sandor L. Varga; Robert G. Denkewalter; Ralph Hirschmann


Journal of Medicinal Chemistry | 1999

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of P38 mitogen-activated protein kinase

Nigel J. Liverton; John W. Butcher; Christopher F. Claiborne; David A. Claremon; Brian Libby; Kevin Nguyen; Steven M. Pitzenberger; Harold G. Selnick; Garry R. Smith; Andrew J. Tebben; Joseph P. Vacca; Sandor L. Varga; Lily Agarwal; Kim Dancheck; Amy J. Forsyth; Daniel S. Fletcher; Betsy Frantz; William A. Hanlon; Coral Harper; Scott J. Hofsess; Matthew Kostura; Jiunn Lin; Sylvie Luell; Edward A. O'Neill; Chad Orevillo; Margaret Pang; Janey Parsons; Anna Rolando; Yousif Sahly; Denise M. Visco


Journal of the American Chemical Society | 1969

Studies on the total synthesis of an enzyme. V. The preparation of enzymatically active material.

Ralph Hirschmann; Ruth F. Nutt; Daniel F. Veber; Ronald A. Vitali; Sandor L. Varga; Theodore A. Jacob; Frederick W. Holly; Robert G. Denkewalter


Journal of Medicinal Chemistry | 1987

Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors

Gerald S. Ponticello; Mark B. Freedman; Charles N. Habecker; Paulette A. Lyle; Harvey Schwam; Sandor L. Varga; Marcia E. Christy; William C. Randall; John J. Baldwin


Journal of Organic Chemistry | 1979

Practical synthesis of cyclic peptides, with an example of dependence of cyclization yield upon linear sequence

Stephen F. Brady; Sandor L. Varga; Roger M. Freidinger; Debra A. Schwenk; Michael Mendlowski; Frederick W. Holly; Daniel F. Veber


Archive | 1992

Pyrroloquinoline Bradykinin antagonist

Keith M. Witherup; Richard W. Ransom; Sandor L. Varga; Steven M. Pitzenberger; Victor J. Lotti; William J. Lumma


Archive | 1975

Analogs of thyrotropin-releasing hormone

Daniel F. Veber; Frederick W. Holly; Ruth F. Nutt; Sandor L. Varga


Journal of the American Chemical Society | 1969

Total synthesis of an enzyme. IV. Factors affecting the conversion of protected S-protein to ribonuclease S'

Daniel F. Veber; Sandor L. Varga; John D. Milkowski; Henry Joshua; John B. Conn; Ralph Hirschmann; Robert G. Denkewalter

Collaboration


Dive into the Sandor L. Varga's collaboration.

Researchain Logo
Decentralizing Knowledge